INmune Bio at H.C. Wainwright conference: rdeB drug nears filings

INmune Bio plans to submit a U.K. marketing application for CORDStrom (Ebstrocel) in Q4 2026, targeting potential U.K. approval in Q2 2027, followed by U.S. and European filings in Q1 2027. The company reported roughly a 70% reduction in itch severity in its RDEB trial and no serious adverse events across more than 200 administrations, supporting its case for a systemic treatment in the ultra-rare disease. However, XPro's Alzheimer’s program remains on hold due to capital prioritization, and the pre-commercial company reported negative $15.73 million in trailing-12-month levered free cash flow despite a current ratio of 4.04.

Analysis

INMB is transitioning from a two-asset story into a single, binary regulatory asset with a financing overhang. Its annual cash burn implies that a Q2-2027 U.K. decision is unlikely to be funded solely from current resources unless cash materially exceeds the limited balance-sheet snapshot; the likely bridge is an equity raise, partnership, or structured financing before U.S./EU submissions and launch preparation. The near-term catalyst is filing acceptance, not approval, but a small-cap biotech with a recent sharp rerating is vulnerable to dilution-driven selloffs well before the regulatory event.

KRYS faces limited immediate revenue displacement because systemic symptom control and wound-directed treatment can be complementary rather than mutually exclusive. The more material risk is payer sequencing: if Ebstrocel gains conditional authorization and demonstrates durable quality-of-life benefit, insurers may require systemic therapy before, or alongside, high-cost topical use, pressuring KRYS net price and duration of therapy in a narrow patient pool. That risk is 12-24 months out and remains speculative because INMB's evidence base, durability, dosing burden, pricing, and confirmatory-trial design have not been independently established.

Consensus appears to be assigning meaningful approval probability to management's regulatory framing while underweighting CMC and evidentiary risk in allogeneic cell therapy. A crossover study can be confounded by carryover effects, particularly when the claimed benefit persists after treatment; regulators may therefore demand more robust confirmation than investors expect. The proposed priority-review-voucher value should be assigned near zero until FDA explicitly accepts an accelerated-approval pathway, and it should not be treated as committed funding for XPro.

Over the next days to weeks, INMB can trade on conference-driven momentum and filing headlines; over 1-3 months, financing terms and formal regulator feedback should dominate; over 6-18 months, approval probability, reimbursement, and manufacturing reproducibility determine value. Falsify the cautious view if INMB discloses cash runway beyond the U.K. decision, non-dilutive funding, and filing acceptance without major CMC remediation; conversely, a discounted raise or delayed submission would challenge the current valuation support.

Key Decisions for Investors

• Do not chase INMB above the recent range on presentation claims. Place it on a catalyst watchlist for the Q4-2026 U.K. submission; consider a small tactical long only after filing acceptance and verified cash runway through at least mid-2027. Risk/reward is unattractive ahead of clarity because dilution can produce a 30-50% drawdown in micro-cap biotech.
• For event-driven exposure, prefer defined-risk INMB calls or call spreads dated after the expected Q2-2027 U.K. decision, but only if listed-option liquidity and implied volatility are acceptable. Cap premium at a level consistent with a binary approval outcome; avoid naked short puts given financing and regulatory gap risk.
• Maintain KRYS as a monitoring short/watch rather than an immediate short. Reassess if INMB receives U.K. approval with a broad label, favorable dosing, and reimbursement evidence; the actionable signal would be KRYS guidance indicating RDEB patient-share loss, net-price pressure, or slower VYJUVEK utilization.
• Avoid assigning value to XPro or a prospective priority review voucher in INMB underwriting until FDA pathway acceptance and financing are disclosed. An equity raise at a material discount, a submission delay, or a request for additional CMC data would be a bearish trigger; confirmed non-dilutive capital would reverse that stance.